| # | Drug | Count |
|---|---|---|
| 0 | TACROLIMUS | 84 |
| 1 | PREDNISONE | 79 |
| 2 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 71 |
| 3 | TACROLIMUS OINTMENT 0.1% | 71 |
| 4 | MYCOPHENOLATE MOFETIL | 60 |
| 5 | MYCOPHENOLATE MOFETIL HYDROCHLORIDE | 60 |
| 6 | ADALIMUMAB | 32 |
| 7 | LENALIDOMIDE | 27 |
| 8 | PREDNISOLONE | 25 |
| 9 | PREDNISOLONE ORAL | 25 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CEMIPLIMAB-RWLC | 5 | 0.0024 |
| 1 | IDECABTAGENE VICLEUCEL | 2 | 0.0016 |
| 2 | ACITRETIN | 6 | 0.0012 |
| 3 | ANTI-THYMOCYTE GLOBULIN (RABBIT) | 7 | 0.0009 |
| 4 | SIROLIMUS | 11 | 0.0008 |
| 5 | CHLORAMBUCIL | 3 | 0.0008 |
| 6 | MYCOPHENILIC ACID | 14 | 0.0007 |
| 7 | MYCOPHENOLIC ACID | 20 | 0.0006 |
| 8 | ACETAMINOPHEN AND DIPHENHYDRAMINE HCL | 2 | 0.0006 |
| 9 | TACROLIMUS OINTMENT 0.1% | 71 | 0.0006 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 137 |
| 1 | Kinase Inhibitor [EPC] | 46 |
| 2 | Tumor Necrosis Factor Blocker [EPC] | 37 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 35 |
| 4 | Thalidomide Analog [EPC] | 32 |
| 5 | Alkylating Drug [EPC] | 27 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 24 |
| 7 | Platinum-based Drug [EPC] | 24 |
| 8 | Platelet Aggregation Inhibitor [EPC] | 21 |
| 9 | CD20-directed Cytolytic Antibody [EPC] | 20 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD38-directed Cytolytic Antibody [EPC] | 12 | 0.0021 |
| 1 | Nitrogen Binding Agent [EPC] | 2 | 0.0008 |
| 2 | Antimetabolite Immunosuppressant [EPC] | 14 | 0.0007 |
| 3 | Sulfonamide Antibacterial [EPC] | 2 | 0.0005 |
| 4 | Neonatal Fc Receptor Blocker [EPC] | 2 | 0.0005 |
| 5 | Provitamin D2 Compound [EPC] | 13 | 0.0004 |
| 6 | CCR5 Co-receptor Antagonist [EPC] | 1 | 0.0004 |
| 7 | Hedgehog Pathway Inhibitor [EPC] | 4 | 0.0004 |
| 8 | Adenosine Receptor Agonist [EPC] | 3 | 0.0004 |
| 9 | Tyrosine Kinase 2 Inhibitor [EPC] | 1 | 0.0003 |